Loading clinical trials...
Loading clinical trials...
The primary objective of this study was to define the dose leading to desirable efficacy, as measured by the change in hemoglobin A1C (A1C) between Baseline and Week 12.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Lexicon Pharmaceuticals
Collaborators
NCT07224321 · Type 1 Diabetes Mellitus
NCT06474598 · Type 1 Diabetes Mellitus
NCT07051005 · Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus (T2DM)
NCT02734277 · Type 1 Diabetes Mellitus, T1DM, and more
NCT07461805 · Type 1 Diabetes Mellitus
Lexicon Investigational Site
Concord, California
Lexicon Investigational Site
Ventura, California
Lexicon Investigational Site
Denver, Colorado
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions